Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

BACKGROUND: Adalimumab is approved for the treatment of hidradenitis suppurativa (HS), plaque psoriasis, and other inflammatory conditions. OBJECTIVE: Our objective was to examine the safety of adalimumab administered every other week (EOW) and every week (EW) in patients with HS and psoriasis and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryan, Caitriona, Sobell, Jeffrey M., Leonardi, Craig L., Lynde, Charles W., Karunaratne, Mahinda, Valdecantos, Wendell C., Hendrickson, Barbara A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945711/
https://www.ncbi.nlm.nih.gov/pubmed/29380251
http://dx.doi.org/10.1007/s40257-017-0341-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945711/
https://www.ncbi.nlm.nih.gov/pubmed/29380251
http://dx.doi.org/10.1007/s40257-017-0341-6

Ejemplares similares